Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Ascletis Pharma, Inc. ( (HK:1672) ) is now available.
Ascletis Pharma Inc. has announced the dosing of the first participants in a U.S. 13-week Phase IIa study of its small molecule oral GLP-1 receptor agonist, ASC30, aimed at treating obesity and overweight individuals with weight-related comorbidities. This study is significant as it evaluates the efficacy, safety, and tolerability of ASC30, which has shown promising results in a previous Phase Ib study with a 6.5% placebo-adjusted mean body weight reduction. The successful development of ASC30 could enhance Ascletis’ position in the obesity treatment market, offering both oral and subcutaneous dosing options, with potential patent protection until 2044.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$3.94 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a biopharmaceutical company focused on developing innovative drugs for the treatment of metabolic diseases, viral infections, and cancer. The company specializes in small molecule drugs, with a particular emphasis on GLP-1 receptor agonists for obesity treatment.
Average Trading Volume: 6,380,098
Technical Sentiment Signal: Buy
Current Market Cap: HK$8.78B
See more data about 1672 stock on TipRanks’ Stock Analysis page.